Literature DB >> 25435195

C-reactive protein as a predictor of cardiovascular risk in HIV-infected individuals.

Clare L V Westhorpe1, Hans G Schneider2, Mandy Dunne1, Tracey Middleton3, Vijaya Sundararajan4, Tim Spelman1, Vanessa Carter5, Suzanne M Crowe1, Anthony Dart6, Anne Mijch7, Despina Kotsanas8, Ian Woolley7.   

Abstract

UNLABELLED: Background In some studies HIV infection confers approximately two-fold higher risk of cardiac events compared with the general population. C-reactive protein (CRP) is a well-characterised biomarker of cardiac events in the general population and is also elevated in patients with HIV infection. The aim of this study was to determine the predictive value of CRP for cardiac events in HIV-infected individuals.
METHODS: We retrospectively analysed CRP levels in stored plasma samples from HIV-infected patients who did or did not experience a coronary event in a case-controlled manner. All CRP measurements were performed using a high-sensitivity assay (hs-CRP).
RESULTS: Of the study participants with samples available, we found slightly elevated hs-CRP levels in the cardiac cases (median 3.5, IQR 1.6-14.4, n=23) compared with controls (median 2.6, IQR1.2-8.3, n=49) which were shown to not be statistically significant P=0.20. Analysis of CRP as a binary variable (≥5mgL(-1)) was also not statistically significant (OR: 1.32, 95% CI 0.48-3.63).
CONCLUSIONS: CRP levels may indicate elevated risk of future cardiac events, however this must be interpreted with caution due to the generalised elevation of CRP during HIV infection. CRP has no predictive value for atherosclerosis, and further research is required to improve early prediction of cardiovascular disease in HIV infection.

Entities:  

Year:  2014        PMID: 25435195     DOI: 10.1071/SH14130

Source DB:  PubMed          Journal:  Sex Health        ISSN: 1448-5028            Impact factor:   2.706


  5 in total

1.  Are Physical Fitness and CRP Related to Framingham Risk Score in HIV+ Adults?

Authors:  John E Lewis; Jillian Poles; Eleanor Garretson; Eduard Tiozzo; Sharon Goldberg; Carmen S G Campbell; Herbert G Simões; Judi M Woolger; Janet Konefal
Journal:  Am J Lifestyle Med       Date:  2020-02-11

2.  Effect of Recombinant Human Growth Hormone and Rosiglitazone for HIV-Associated Abdominal Fat Accumulation on Adiponectin and other Markers of Inflammation.

Authors:  Vivien Leung; Ya-Lin Chiu; Donald P Kotler; Jeanine Albu; Yuan-Shan Zhu; Kirsis Ham; Ellen S Engelson; Hoda Hammad; Paul Christos; Daniel S Donovan; Henry N Ginsberg; Marshall J Glesby
Journal:  HIV Clin Trials       Date:  2016-02-01

3.  Cardiovascular outcomes among HIV-infected veterans receiving atazanavir.

Authors:  Joanne LaFleur; Adam P Bress; Lisa Rosenblatt; Jacob Crook; Paul E Sax; Joel Myers; Corey Ritchings
Journal:  AIDS       Date:  2017-09-24       Impact factor: 4.177

Review 4.  C-Reactive Protein as an Independent Cardiovascular Risk Predictor in HIV+ Patients: A Focused Review of Published Studies.

Authors:  Tarvinder S Gilotra; Stephen A Geraci
Journal:  J Clin Med Res       Date:  2017-10-02

5.  Evaluation of Platelet Activation by HIV Protease Inhibitors - The HIV-PLA II Study.

Authors:  Gerrit Kann; Junaid Owasil; Karina Kuczka; Annette Haberl; Timo Wolf; Pavel Khaykin; Sebastian Harder; Christoph Stephan; Nils von Hentig
Journal:  HIV AIDS (Auckl)       Date:  2021-08-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.